97,845 Definium Therapeutics, Inc. $DFTX Shares Purchased by Moody Aldrich Partners LLC

Key Points

• Moody Aldrich Partners increased its Definium Therapeutics stake by 191.8% in the third quarter, purchasing 97,845 additional shares and bringing its total holdings to 148,870 shares worth approximately $5.7 million.
• Institutional investors own 27.91% of Definium Therapeutics, while insiders own 2.40%; insiders sold 71,098 shares worth $2.6 million over the past three months under pre-arranged trading plans.
• DFTX recently traded at $38.10, well below the analyst consensus price target of $66.00. Analysts hold a “Moderate Buy” consensus, although the company missed its latest quarterly EPS estimates and is expected to remain unprofitable this fiscal year.

Moody Aldrich Partners LLC grew its stake in Definium Therapeutics, Inc. (NASDAQ:DFTX - Free Report) by 191.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 148,870 shares of the company's stock after purchasing an additional 97,845 shares during the period. Definium Therapeutics comprises about 1.1% of Moody Aldrich Partners LLC's investment portfolio, making the stock its 29th biggest position. Moody Aldrich Partners LLC owned about 0.11% of Definium Therapeutics worth $5,666,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Wellington Management Group LLP bought a new position in shares of Definium Therapeutics during the 2nd quarter worth about $138,755,000. Seven Fleet Capital Management LP acquired a new position in shares of Definium Therapeutics during the second quarter valued at about $6,992,000. TD Waterhouse Canada Inc. bought a new stake in shares of Definium Therapeutics in the second quarter valued at about $1,592,000. Arizona State Retirement System bought a new stake in shares of Definium Therapeutics in the second quarter valued at about $1,431,000. Finally, Stableford Capital II LLC bought a new stake in shares of Definium Therapeutics in the second quarter valued at about $1,277,000. Institutional investors own 27.91% of the company's stock.

Insider Buying and Selling at Definium Therapeutics

In other Definium Therapeutics news, insider Matthew T. Wiley sold 3,097 shares of the firm's stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $36.57, for a total transaction of $113,257.29. Following the completion of the transaction, the insider owned 359,036 shares in the company, valued at $13,129,946.52. This trade represents a 0.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert Barrow sold 31,550 shares of the firm's stock in a transaction dated Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $1,153,783.50. Following the transaction, the chief executive officer owned 2,213,090 shares of the company's stock, valued at approximately $80,932,701.30. This represents a 1.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 71,098 shares of company stock worth $2,626,115. Insiders own 2.40% of the company's stock.

Definium Therapeutics Trading Up 2.8%

Shares of DFTX stock opened at $38.10 on Thursday. Definium Therapeutics, Inc. has a 52-week low of $10.46 and a 52-week high of $49.70. The stock has a market cap of $5.12 billion, a price-to-earnings ratio of -11.11 and a beta of 2.19. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95. The firm has a fifty day moving average of $38.11 and a 200-day moving average of $29.28.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.89). On average, equities research analysts forecast that Definium Therapeutics, Inc. will post -3.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on DFTX shares. Wells Fargo & Company lifted their target price on Definium Therapeutics from $68.00 to $72.00 and gave the stock an "overweight" rating in a research report on Thursday, August 13th. Stifel Nicolaus upped their price target on Definium Therapeutics from $30.00 to $60.00 and gave the company a "buy" rating in a report on Wednesday, July 8th. HC Wainwright reiterated a "buy" rating and issued a $70.00 price objective on shares of Definium Therapeutics in a research report on Monday, September 14th. Needham & Company LLC reissued a "buy" rating and set a $66.00 price objective on shares of Definium Therapeutics in a report on Monday, September 14th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Definium Therapeutics in a report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Definium Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $66.00.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

Want to see what other hedge funds are holding DFTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Definium Therapeutics, Inc. (NASDAQ:DFTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.